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ABSTRACT Method-dependent Etest epidemiological cutoff values (ECVs) are not
available for susceptibility testing of either Candida or Aspergillus species with am-
photericin B or echinocandins. In addition, reference caspofungin MICs for Candida
spp. are unreliable. Candida and Aspergillus species wild-type (WT) Etest MIC distribu-
tions (microorganisms in a species-drug combination with no detectable phenotypic
resistance) were established for 4,341 Candida albicans, 113 C. dubliniensis, 1,683 C.
glabrata species complex (SC), 709 C. krusei, 767 C. parapsilosis SC, 796 C. tropicalis,
1,637 Aspergillus fumigatus SC, 238 A. ﬂavus SC, 321 A. niger SC, and 247 A. terreus
SC isolates. Etest MICs from 15 laboratories (in Argentina, Europe, Mexico, South Af-
rica, and the United States) were pooled to establish Etest ECVs. Anidulafungin,
caspofungin, micafungin, and amphotericin B ECVs (in micrograms per milliliter) en-
compassing 97.5% of the statistically modeled population were 0.016, 0.5, 0.03,
and 1 for C. albicans; 0.03, 1, 0.03, and 2 for C. glabrata SC; 0.06, 1, 0.25, and 4 for C.
krusei; 8, 4, 2, and 2 for C. parapsilosis SC; and 0.03, 1, 0.12, and 2 for C. tropicalis.
The amphotericin B ECV was 0.25 g/ml for C. dubliniensis and 2, 8, 2, and 16 g/ml
for the complexes of A. fumigatus, A. ﬂavus, A. niger, and A. terreus, respectively.
While anidulafungin Etest ECVs classiﬁed 92% of the Candida fks mutants evaluated
as non-WT, the performance was lower for caspofungin (75%) and micafungin (84%)
cutoffs. Finally, although anidulafungin (as an echinocandin surrogate susceptibility
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marker) and amphotericin B ECVs should identify Candida and Aspergillus isolates
with reduced susceptibility to these agents using the Etest, these ECVs will not cate-
gorize a fungal isolate as susceptible or resistant, as breakpoints do.
KEYWORDS ECVs, Etest ECVs, Etest MICs Candida, Etest MICs Aspergillus, WT
isolates, amphotericin B resistance, antifungal resistance, echinocandin resistance,
non-WT, susceptibility marker
The incidence and prevalence of invasive infections caused by Candida, Aspergillus,and other fungal pathogens continue to increase, especially among immunocom-
promised patients and those with serious underlying diseases; their attributable mor-
tality rates can be as high as 47% depending on the patient population and age (1–4).
Three echinocandins (anidulafungin, caspofungin, and micafungin) have been licensed
for intravenous treatment and prevention of invasive Candida infections (including
candidemia) (5). The echinocandins and amphotericin B also serve as alternative
choices to the triazoles as salvage, empirical, prophylactic, and/or adjunctive therapies
for invasive aspergillosis (6).
The Clinical and Laboratory Standards Institute (CLSI) and European Committee on
Antimicrobial Susceptibility Testing (EUCAST) have established standard guidelines for
testing the susceptibilities of Candida spp. to echinocandins, including species-speciﬁc
breakpoints (BPs) and epidemiological cutoff endpoints (ECVs) for MIC interpretation
(7–13). While both organizations also have developed standard methodologies for
testing amphotericin B against Candida and Aspergillus spp. (7, 12, 14), CLSI has set ECVs
and EUCAST BPs for various Candida and Aspergillus species (10, 11, 15–17). Species-
speciﬁc BPs predict the likelihood of clinical success of treatment. In the absence of BPs,
the method-dependent and species-speciﬁc ECVs should identify non-WT isolates with
reduced susceptibility to the agent under evaluation due to acquired mutational or
other resistance mechanisms (11, 18). In the case of Candida isolates, echinocandin-
resistant and/or non-WT isolates often harbor amino acid substitutions in Fks1p (and/or
Fks2p in C. glabrata) genes and have been associated with breakthrough candidiasis
(19) or treatment failure (20). Similar information is not available for amphotericin B,
given that polyene resistance mechanisms in Aspergillus, Candida, or any fungal species
are not yet as clearly determined/understood and resistance is unusual.
Signiﬁcant interlaboratory variability in caspofungin modal MICs (wide modal
ranges) precludes routine testing or reporting of reference caspofungin MICs for
Candida spp. derived by both CLSI and EUCAST methodologies (21); unreliable MICs
could lead to incorrectly interpreting susceptibility results. However, caspofungin
modal variability does not pose a problem when using the Sensititre YeastOne (SYO)
colorimetric method for susceptibility testing of Candida spp. and echinocandins (22),
which prompted the establishment of method-dependent echinocandin SYO ECVs for
Candida spp. (23). Another commercial and frequently used method for antifungal
susceptibility testing is the gradient agar diffusion-based Etest assay (bioMérieux, Marcy
l’Etoile, France) (24). Both commercial methods recommend the use of CLSI interpretive
criteria of MIC results for Candida spp. (23, 25). ECVs could be useful in the surveillance
of in vitro resistance and to distinguish between phenotypic wild-type (WT; no detect-
able phenotypic resistance) and non-WT isolates that are less likely to respond to
contemporary therapy. This is important when limited clinical data have precluded the
development of BPs for most fungal species.
The ECV is the highest MIC/MEC (minimum effective concentration) in a distribution
of the WT population and is established by using reliable MIC/MEC distributions from
multiple laboratories. Therefore, we have pooled Etest MIC data from multiple labora-
tories to deﬁne method-dependent Etest ECVs for species of Candida and Aspergillus
versus echinocandins and amphotericin B. These data are representative of the sus-
ceptibility of these species to the agents evaluated by the Etest. Although caspofungin
MEC distributions for Aspergillus spp. were also collected, signiﬁcant heterogeneity in
the respective modal MECs, similar to that described for reference caspofungin and
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Candida spp. MIC distributions (21), precluded the establishment of Etest ECVs for
species of Aspergillus and caspofungin; these results will be presented separately.
In the present study, we have (i) aggregated echinocandin and amphotericin B MICs
generated using the Etest agar diffusion method originating from 3 to 10 laboratories
for six Candida species (Candida albicans, C. dubliniensis, C. glabrata species complex
[SC], C. krusei [Issatchenkia orientalis], C. parapsilosis SC, and C. tropicalis) and four
Aspergillus species complexes (A. fumigatus, A. ﬂavus, A. niger, and A. terreus) in order to
deﬁne the WT MIC distributions of amphotericin B, anidulafungin, caspofungin, and
micafungin; and (ii) have proposed method-dependent Etest ECVs for each of these
amphotericin B- and echinocandin-species combinations for which the number of Etest
MIC values was at least 100. Additional MIC distributions comprising MIC values from
25 to 62 isolates of less prevalent species (C. guilliermondii [Meyerozyma guilliermondii],
C. lusitaniae [Clavispora lusitaniae], and C. kefyr [Kluyveromyces marxianus]) were also
documented. Echinocandin and amphotericin B MICs for 25 to 4,341 isolates (species
and agent dependent) were pooled by using data collected in 3 to 10 (of 15) inde-
pendent laboratories (in Argentina, Europe, Mexico, South Africa, and the United
States).
Given that most of the isolates included in the study were not assessed for
mechanisms of resistance, we evaluated the application of our ECVs using Etest MIC
data for individual well-characterized non-WT (isolates harboring mechanisms of resis-
tance or fks1 and fks2 gene mutations) (19, 26–33) and WT (no phenotypic resistance
or fks gene mutations) isolates, in the same manner that CLSI and SYO echinocandin
ECVs were evaluated in previous studies (9, 23).
RESULTS AND DISCUSSION
BPs are unique and reliable predictors of clinical response to therapy for the
isolate/agent being evaluated. Both CLSI and EUCAST have established BPs for the
more prevalent Candida spp. and some antifungal agents (8, 17). Although BPs are not
available for most fungal species-agent combinations, CLSI ECVs have been established
for more fungal species (both prevalent and less common) based solely on reference in
vitro data (10, 11, 18). The Etest method has been extensively evaluated for testing both
yeasts and molds and the antifungal agents included in the present study (34–41) to
estimate essential and categorical agreement with reference methods or the potential
Etest’s superior value as a predictor of antifungal resistance. Given that the Etest relies
on CLSI BPs for clinical interpretation of results, method-dependent Etest ECVs could be
useful in the clinical setting. In this study, we have proposed Etest ECVs for three
echinocandins and amphotericin B and the six more prevalent species of Candida, as
well as amphotericin B ECVs for four complexes of Aspergillus, according to the criteria
set forth by the CLSI (10, 11) (see Table 3). These Etest ECVs could aid the clinician and
laboratory personnel in identifying echinocandin and amphotericin B potential resis-
tance (non-WT isolates) instead of relying on CLSI interpretive criteria (BPs) (25); they
also could be most useful for surveillance or epidemiological purposes, especially for
amphotericin B resistance, which is rare.
Although Etest MIC data were received from 15 laboratories, not all laboratories
provided distributions for all species and agents evaluated. There were also exclusions
due to either aberrant (mode at the lowest concentration tested) or bimodal distribu-
tions or when MICs for the quality control (QC) isolates were outside the recommended
range (10, 11) The aggregated Etest MIC distributions of the three echinocandins for the
common and less prevalent Candida spp. included are listed in Table 1. Table 2 presents
pooled Etest MIC data of amphotericin B for species and SC of Candida and Aspergillus.
The Etest echinocandin and amphotericin B modal MICs from individual participant
laboratories were similar for each species-agent combination evaluated (within one
2-fold dilution). However, that was not the case among caspofungin MECs for Asper-
gillus spp., as mentioned above (data not included in Tables 1 and 2). In contrast, modal
MEC variability was not observed in the study that established CLSI ECVs for caspo-
fungin and Aspergillus spp. (42). As expected, caspofungin MIC modes for Candida spp.
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were higher than those of anidulafungin or micafungin; the exception was the anidu-
lafungin mode for C. parapsilosis SC (2 versus 0.5 g/ml) (Tables 1 and 3). Overall, the
modes of anidulafungin were substantially lower than those of the other two echino-
candins (Candida spp.) and amphotericin B (both species of Candida and Aspergillus),
with the exception noted above for the combination of anidulafungin and C. parapsi-
losis SC. The highest amphotericin B modes were for C. krusei (1 g/ml), A. ﬂavus SC (2
g/ml), and A. terreus SC (4 g/ml) (Tables 2 and 3). In general, similar Etest data have
been previously published (34–41), but as observed in prior ECV studies, our MIC ranges
tended to be wider, especially for Candida spp. versus anidulafungin and micafungin.
Table 3 also summarizes the proposed Etest ECVs for the species and agents with
sufﬁcient data to fulﬁll the current criteria (100 Etest MICs of each echinocandin or
amphotericin B from3 laboratories) for establishing method-dependent ECVs (10, 11).
TABLE 1 Echinocandin pooled MIC distributions for species of Candidac
Agent and
speciesa
No. of
laboratories
No. of
isolates
tested
No. of isolates with MIC (g/ml) ofb:
0.002 0.004 0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 >8
Anidulafungin
C. albicans 6 988 132 288 362 107 31 31 18 9 5 4 1
C. glabrata SC 5 461 1 15 58 281 69 17 9 6 2 1 1 1
C. krusei 6 198 7 51 91 27 10 7 3 1 1
C. parapsilosis SC 4 309 2 2 3 4 13 20 84 107 47 27
C. tropicalis 5 197 3 18 46 97 20 7 3 2 1
Caspofungin
C. albicans 9 2,537 9 26 151 549 876 596 263 52 4 2 9
C. glabrata SC 10 1,148 3 10 22 77 287 446 237 51 10 4 1
C. krusei 5 189 1 3 2 45 115 19 3 1
C. parapsilosis SC 6 631 2 2 6 56 79 209 199 53 14 11
C. tropicalis 8 796 16 23 131 176 266 148 30 6
C. guilliermondii 3 25 1 4 8 5 4 2 1
C. kefyr 3 27 1 6 6 12 2
Micafungin
C. albicans 6 878 19 74 278 333 95 34 18 6 8 7 1 5
C. glabrata SC 6 381 6 72 139 121 18 13 7 4 1
C. krusei 4 139 4 10 41 63 15 4 2
C. parapsilosis SC 6 336 4 6 15 18 168 81 35 8 1
C. tropicalis 5 140 4 16 31 48 25 10 4 1 1
aSC, species complex.
bThe highest number in each row (showing the most frequently obtained MIC or the mode) is in boldface.
cData are from between 3 and 10 laboratories and were determined by the commercial Etest agar diffusion method.
TABLE 2 Amphotericin B pooled MIC distributions for species of Candida and Aspergillusc
Speciesa
No. of
laboratories
No. of
isolates
tested
No. of isolates with MIC (g/ml) ofb:
<0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 >8
C. albicans 9 4,341 58 112 269 559 1,079 1,435 701 94 24 10
C. glabrata SC 8 1,683 3 5 16 39 134 347 785 287 55 11 1
C. dubliniensis 4 113 5 10 12 45 27 9 5
C. krusei 6 709 1 8 11 18 26 95 190 250 91 15 4
C. parapsilosis SC 7 767 2 5 15 69 90 224 236 90 24 12
C. tropicalis 9 645 1 12 14 36 68 161 213 106 24 9 1
C. guilliermondii 4 54 1 6 15 19 8 3 2
C. kefyr 3 54 9 11 23 9 2
C. lusitaniae 4 62 2 17 17 22 12 2
A. fumigatus SC 10 1,637 1 6 11 102 260 726 446 61 13 11
A. ﬂavus SC 6 238 3 12 18 63 79 42 21
A. niger SC 7 321 1 2 2 24 92 135 48 15 1 1
A. terreus SC 6 247 2 3 9 36 69 85 43
aSC, species complex.
bThe highest number in each row (showing the most frequently obtained MIC or the mode) is in boldface.
cData are from between 3 and 10 laboratories and were determined by the commercial Etest agar diffusion method.
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Method-dependent caspofungin Etest ECVs for Candida spp. and amphotericin B ECVs
for both Candida and Aspergillus were consistently either the same or higher (one to
two dilutions) than those for the SYO or CLSI methods (9, 11, 23). In contrast, available
ECVs of the other two echinocandins were either mostly the same (micafungin) or up
to three dilutions lower (anidulafungin). Overall, EUCAST ECVs were more comparable
to Etest cutoffs (17). These discrepancies among the ECVs for those different method-
ologies emphasize the importance of using the interpretation criteria of the method
used to obtain the susceptibility testing result. The high ECVs for certain species (values
above expected and achievable serum levels) indicate the resistant nature of these
species to the agent evaluated and suggest that they could be unresponsive to therapy
with that agent. After all, a categorization of an isolate as WT does not necessarily
signify that it is susceptible or treatable.
Table 4 depicts the ability of the proposed echinocandin Etest ECVs to identify
non-WT Candida isolates (with fks1 [all species] or fks2 [C. glabrata only] gene muta-
tions). The total of 140 molecularly deﬁned echinocandin mutants included 60 C.
albicans, 51 C. glabrata, 18 C. krusei, and 11 C. tropicalis isolates (19, 26–33). However,
anidulafungin and micafungin Etest MICs were only available for 116 and 102 strains,
TABLE 3Method-dependent Etest ECVs of caspofungin, anidulafungin, micafungin, and amphotericin B for species of Candida and
Aspergillusf
Agent and
speciesa
No. of
isolates
tested
MIC (g/ml) Method-dependent ECVse (g/ml)
Range Modeb Etestc (>97.5%) SYO (97.5%) CLSI (>97.5%) EUCAST
Anidulafungin
C. albicans 988 0.002–4 0.008 0.016 0.12 0.12 0.03
C. glabrata SC 461 0.002–8 0.016 0.03 0.12 0.12 0.06
C. krusei 189 0.008–8 0.03 0.06 0.25 0.25 0.06
C. parapsilosis SC 309 0.016–32 2 8/8d 4 8 4
C. tropicalis 197 0.002–4 0.016 0.03 0.5 0.06 0.06
Caspofungin
C. albicans 2,537 0.08–32 0.12 0.5 0.25 NA NA
C. glabrata SC 1,148 0.08–32 0.25 1 0.25 NA NA
C. krusei 189 0.016–8 0.5 1 1 NA NA
C. parapsilosis SC 631 0.08–32 0.5 4 2 NA NA
C. tropicalis 796 0.016–2 0.25 1/1d 0.25 NA NA
Micafungin
C. albicans 878 0.002–4 0.16 0.03 0.06 0.03 0.015
C. glabrata SC 381 0.002–0.5 0.008 0.03 0.03 0.03 0.03
C. krusei 139 0.016–1 0.12 0.25 0.25 0.25 0.25
C. parapsilosis SC 336 0.03–16 0.5 2 4 4 2
C. tropicalis 140 0.004–1 0.03 0.12/0.12d 006 0.06 0.06
Amphotericin B
C. albicans 4,341 0.008–4 0.25 1 NA 2 1
C. glabrata SC 1,683 0.016–16 0.5 2 NA 2 1
C. krusei 709 0.008–32 1 4 NA 2 1
C. parapsilosis SC 767 0.016–4 0.5 2 NA 2 1
C. tropicalis 645 0.008–32 0.5 2 NA 2 1
C. dubliniensis 113 0.008–0.5 0.06 0.25/0.5d NA NA NA
Amphotericin B
A. fumigatus SC 1,637 0.016–32 0.5 2 NA 2 1
A. ﬂavus SC 238 0.12–32 2 8 NA 4 4
A. niger SC 321 0.016–8 0.5 2 NA 2 1
A. terreus SC 247 0.12–32. 4 16 NA 4 4
aSC, species complex.
bMost frequent MIC in the distribution. NA, not available.
cCalculated Etest ECVs comprising 97.5% of the statistically modeled population; SYO, CLSI, and EUCAST ECVs based on MICs determined by the SYO (23), CLSI
M27A-3 (9), and EUCAST (denominated as ECOFFS; www.eucast.org [12]) broth dilution methods in previous studies.
dECVs obtained before and after normalization of data for the analysis, when the distribution of one of the laboratories provided 50 of the data (10, 11).
eNA, not available.
fData are based on MICs from between 3 and 10 laboratories determined by the commercial Etest agar diffusion method.
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respectively. Despite that, Etest anidulafungin ECVs of 0.016 g/ml for C. albicans, 0.03
g/ml for C. glabrata SC, 0.06 g/ml for C. krusei, and 0.03 g/ml for C. tropicalis
correctly classiﬁed 107 of those 116 (92%) mutants as non-WT (MICs were greater than
the ECVs). Performance of Etest ECVs of anidulafungin was similar to those for SYO
(89%) and CLSI (92%) ECVs for the same Candida spp. (9, 23). On the other hand, using
the cutoffs listed in Tables 3 and 4 for caspofungin and micafungin, the Etest correctly
identiﬁed a much lower number of mutants (75 and 84%, respectively) than CLSI (100%
with micafungin cutoffs), SYO (91% and 94 with caspofungin and micafungin cutoffs,
respectively) (9, 23), and our Etest anidulafungin ECVs (Table 4). The Etest dip effect
phenomenon that appears to increase caspofungin MICs for common Candida spp.
(especially for values of 0.25 g/ml) may explain the lower performance of our Etest
caspofungin ECVs in identifying Candida mutants (43). However, it does not explain the
similarly poor performance of the micafungin Etest ECVs. The main problem was with
C. glabrata SC (Table 4). The presence of FKS gene mutations in isolates is not always
associated with in vitro or phenotypic resistance; we observed that among the mutants
for which anidulafungin Etest MICs were available, the same gene mutation was
present in four isolates of C. albicans, FKS1 S645F (2 isolates) and S645P (2 isolates)
(Table 4). Testing caspofungin or micafungin by the Etest is probably not the best
approach until more Etest data for Candida mutants, especially for micafungin, are
available. Given the increasing incidence of echinocandin resistance among Candida
spp. (C. glabrata in particular), evaluating the susceptibilities of Candida isolates to
anidulafungin using the Etest can serve as a more speciﬁc surrogate marker for
emerging echinocandin resistance, as has been suggested for CLSI and EUCAST meth-
odologies and caspofungin (44).
As mentioned above, similar genetic information is not available for amphotericin B
and species of either Candida or Aspergillus. Although in the 1990s the Etest was
reported to be superior to the CLSI method in its ability to detect amphotericin B
resistance (based on in vivo, not genotypic, data) in Candida spp. (45), that study only
included one isolate each of C. albicans and C. tropicalis (Etest MICs, 32 g/ml).
TABLE 4 Application of method-dependent Etest ECVs of caspofungin, anidulafungin, and
micafungin to identify non-WT Candida strains harboring fks1 and fks2 gene mutationsa
Agent and species
No. of mutants
identiﬁed/no.
testedb (%)
No. of mutants
ECVc (g/ml)Below ECV At ECV Above ECV
Caspofungin
C. albicans 51/60 (85) 7 2 51 0.5
C. glabrata 34/51 (67) 12 5 34 1
C. krusei 11/18 (61) 6 1 11 1
C. tropicalis 9/11 (ND) 0 2 9 1
Total 105/140 (75)
Anidulafungin
C. albicans 48/55 (87) 1 6 48 0.016
C. glabrata 36/37(97) 0 1 36 0.03
C. krusei 14/15 (93) 0 1 14 0.06
C. tropicalis 9/9 (ND) 0 0 9 0.03
Total 107/116 (92)
Micafungin
C. albicans 43/50 (86) 5 2 43 0.03
C. glabrata 27/31 (87) 1 3 27 0.03
C. krusei 8/12 (67) 4 0 8 0.25
C. tropicalis 8/9 (ND) 0 1 8 0.12
Total 86/102 (84)
aMutation data are from references 19 and 26–33.
bGene mutations present in the isolates misclassiﬁed as WT among the isolates for which anidulafungin data
were available were the following: C. albicans, FKS1 L644L/stop F641L S645F (2 isolates) and R647I S645P (2
isolates); C. glabrata, FKS2 K1323E; C. krusei, FKS1 T657I L660I. ND, not determined due to small values.
cCalculated Etest ECVs comprising 97.5% of the statistically modeled population.
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Amphotericin B MICs for the four resistant C. lusitaniae isolates evaluated in that study
were 1 to 4 g/ml; it is interesting that 1 g/ml was the upper value for the pooled
amphotericin B MIC distribution for this species from the four laboratories that pro-
vided those data in our study (Table 2). Most of the method-dependent ECVs of
amphotericin B in Table 3, especially for Aspergillus spp., are the same as or above the
expected serum concentrations by contemporary dosages, as well as above the con-
ventional and EUCAST susceptible BPs of 1 g/ml. ECVs that could be beyond achiev-
able serum concentrations have previously been deﬁned (for Fusarium spp., among
others) as well as in the present study (echinocandins and C. parapsilosis) (Table 3) (9,
11, 23). They indicate the intrinsic resistant nature of those species to available agents
and that they could be unresponsive to treatment with contemporary therapy. For
example, most amphotericin B MICs for A. terreus isolates are high in this and other
studies (mode, 4 g/ml; Table 3), and dissemination and poor outcomes with the
different amphotericin B formulations are usually observed (6, 15, 16). However, there
are other factors that can have or have more inﬂuence on the patient’s response to
therapy. The scarcity of clinical data showing a relationship between low and high
MICs/MECs and response to therapy precludes more conclusive statements and the
establishment of CLSI amphotericin B BPs versus any fungal pathogen and by the
EUCAST for a few species. When the clinical BP is available for the method used for
susceptibility testing for the isolate and agent evaluated, that BP is the endpoint that
must be used. It is noteworthy that most available anidulafungin and micafungin ECVs
by the different methods (Table 3) are below the CLSI susceptible BPs (8); the excep-
tions again are the ECVs for C. parapsilosis.
In conclusion, we propose method-dependent and species-speciﬁc Etest ECVs of
anidulafungin for C. albicans, C. glabrata SC, C. krusei, C. parapsilosis SC, and C. tropicalis
of 0.016 g/ml, 0.03 g/ml, 0.06 g/ml, 8 g/ml, and 0.03 g/ml, respectively. The
anidulafungin ECVs and the Etest method were able to identify 92% of the mutants as
non-WT isolates, which is the role of the ECV. In the meantime, given that the overall
performance of method-dependent Etest ECVs of caspofungin and micafungin was
much lower (75 and 84%, respectively), the anidulafungin Etest ECVs may serve as a
surrogate marker to screen for echinocandin resistance in Candida spp. by this method
until further information is gathered for micafungin data for mutants. We also have
proposed species-speciﬁc and method-dependent Etest ECVs of amphotericin B of 1
g/ml for C. albicans, 0.25 g/ml for C. dubliniensis, 2 g/ml for C. glabrata SC, 4 g/ml
for C. krusei, 2 g/ml for C. parapsilosis SC, and 2 g/ml for C. tropicalis, as well as ECVs
of 2 g/ml for the complexes of A. fumigatus and A. niger, 8 g/ml for A. ﬂavus, and 16
g/ml for A. terreus. Due to the lack of BPs for the interpretation of Etest MICs for these
agent-species-SC combinations, the ECVs proposed in our study for Candida spp.
(amphotericin B and anidulafungin) and Aspergillus spp. (amphotericin B) should aid
laboratory personnel as well as physicians in identifying those non-WT isolates having
presumptive acquired echinocandin or amphotericin B resistance mechanisms. How-
ever, the ECV does not categorize an isolate as susceptible or resistant to the agent
evaluated as breakpoints do, because they do not account for the pharmacology of the
antifungal agent or the ﬁndings from clinical outcome studies.
MATERIALS AND METHODS
Isolates. The isolates evaluated were recovered from blood cultures, patients with candidemia
(90%), deep infections, other sterile sites, and other sites (bronchoalveolar lavage ﬂuid, sputum, and
other respiratory related infections [most Aspergillus species isolates]) (90%). Antifungal susceptibility
testing for each nonserial unique isolate was performed by the Etest gradient agar diffusion-based
method by following the manufacturer’s instructions (24) at the following medical centers: VCU Medical
Center, Richmond, VA, USA; Unit for Mycology, Statens Serum Institut, Copenhagen, Denmark; Grupo
Infección Grave, Instituto Investigación Sanitaria La Fe, Valencia, Spain; Instituto Nacional de Enfer-
medades Infecciosas Dr. C. G. Malbrán, Buenos Aires, Argentina; Hôpital Européen Georges Pompidou,
Paris, France; Hospital Universitario La Paz, Madrid, Spain; Universidad Autonóma de Nuevo León,
Monterrey, Nuevo León, México; National Institute for Communicable Diseases, Johannesburg, South
Africa; Hospital Valme, Seville, Spain; Division of Hygiene and Medical Microbiology, Medical University
of Innsbruck, Innsbruck, Austria; Facultad de Medicina, Universidad de Córdoba, H. U. Reina Sofía,
Córdoba, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Servicio de Microbiología, Hospital
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Universitario Central de Asturias, Asturias, Spain; and University of Pittsburgh Medical Center, Pittsburgh,
PA, USA.
Although MICs were received from 15 laboratories (coded 1 to 15), some laboratories only provided
data for either Candida or Aspergillus species. Therefore, the data used for the analyses of each
species-agent combination originated from 3 to 10 laboratories (Tables 1 and 2). Isolates of Candida spp.
were identiﬁed at each laboratory using conventional methodologies (e.g., morphology on cornmeal-
Tween 80 agar, growth at 45°C, API 32C AUX yeast identiﬁcation system [bioMérieux], Vitek yeast
biochemical card [bioMérieux], or mass spectrometry since 2010 [matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry; Bruker Corporation, Billerica, MA, USA]) or both phenotypic
and/or molecular identiﬁcation as needed (e.g., when the phenotypic proﬁles were inconclusive and
were from the laboratories that reported data for the less prevalent species [internal transcribed spacer
sequencing for Candida spp.]) (46). Isolates of Aspergillus spp. were also identiﬁed by conventional (both
macro- and micromorphology and thermotolerance at 50°C) and molecular (mass spectrometry and
internal transcribed spacer sequencing) methodologies to the species complex level (47).
We pooled the collected Etest MIC data of each agent for 4,341 C. albicans, 113 C. dubliniensis, 1,683
C. glabrata SC (C. glabrata sensu stricto, C. nivariensis, and C. bracarensis), 709 C. krusei, 767 C. parapsilosis
SC (C. parapsilosis sensu stricto, C. metapsilosis, and C. orthopsilosis), and 796 C. tropicalis isolates, as well
as for other less prevalent species from three to four laboratories (C. guilliermondii, C. lusitaniae, and C.
kefyr) (Tables 1 and 2). We also pooled data for the four most prevalent complexes of Aspergillus (1,637
A. fumigatus, 238 A. ﬂavus, 321 A. niger, and 247 A. terreus isolates) originating from 6 to 10 independent
laboratories. One or both QC isolates (C. parapsilosis ATCC 22019 and C. krusei ATCC 6258) were used
during testing by the participant laboratories (22).
Etest MICs for 140 isolates tested for the presence of fks1 or fks2 gene mutations (non-WT strains) (19,
26–33), and 37 WT (no fks gene mutations) isolates also were used to assess the ability of proposed Etest
ECVs of anidulafungin, caspofungin, and micafungin to identify non-WT Candida isolates. Etest MICs for
these isolates were obtained in six of the participant laboratories. To our knowledge, similar information
is not available for amphotericin B and either Candida or Aspergillus species.
Antifungal susceptibility testing. MICs were obtained at each center by following the manufac-
turer’s instructions for the Etest agar diffusion-based method (ﬁnal inoculum concentrations to the
turbidity of a 0.5 McFarland standard, solidiﬁed [1.5% agar] RPMI 1640 medium with 2% glucose, and
Etest gradient concentration strips that ranged from 0.002 to 32 g/ml) (24). Etest MICs were obtained
by visual observation after 24 h of incubation (or when sufﬁcient growth permitted MIC determination),
and the MIC was the lowest drug concentration at which the pointed end of the inhibition ellipse
intercepted the scale on the antifungal strip; small colonies inside the ellipse were ignored for echino-
candins but not for amphotericin B (24).
Caspofungin discrepant MICs (lower) for the QC strains were occasionally reported for both QC C.
parapsilosis ATCC 22019 and C. krusei ATCC 6258 isolates, as well as for the QC strain C. parapsilosis ATCC
22019 with amphotericin B. However, MIC data were not included in the pooled distributions used for
the calculation of ECVs unless the data for QC reference strains (C. krusei ATCC 6258 and C. parapsilosis
ATCC 22019) were within the MIC limits listed in the informational table provided by the manufacturer
(25).
Deﬁnitions. The deﬁnition of the ECV, as well as of the two populations (WT and non-WT MIC
populations/isolates), have been widely provided in detail elsewhere and described above (10, 11, 18).
A non-WT organism shows reduced susceptibility to the agent being evaluated compared to the WT (no
phenotypic resistance) population. In addition to MIC distributions, the ECV calculation took into account
each laboratory distribution mode, the inherent variability of the test (usually within one doubling
dilution), and that the ECV should encompass 97% of isolates. Most published ECVs are based on
reference MIC distributions, and ECVs based on other methods could be different. We used the same
criteria and requirements for establishing CLSI and SYO method-dependent ECVs for proposed Etest
cutoffs in the present study.
Data analysis. Data were analyzed as previously described (10, 11, 18), but Etest MICs were
converted to the reference double dilution MIC scales (Tables 1 and 2). Etest MIC distributions of each
species-SC-echinocandin-amphotericin B combination received from each center were listed in Microsoft
Excel spreadsheets. Pooled distributions from 3 laboratories and 100 isolates were screened for (i)
abnormal distributions (truncated distributions that had the mode at the lowest or highest concentration
tested and/or that were bimodal inside the presumptive wild-type distribution), (ii) presumptive wild-
type modes of more than one 2-fold dilution from the most common mode, and (iii) the percentage of
isolates provided by each laboratory for each species-agent combination. For the few occasions when
one of the laboratories included in the pooled distribution provided 50% of the MIC data, such MIC
distributions were weighted (or normalized) to reduce bias in the estimate (Table 3). However, decisions
have not been made regarding the preferred ECV when the two values are different, e.g., the ECV for C.
dubliniensis and amphotericin B and others (Table 3). Following the elimination of abnormal distributions,
the resulting qualifying pooled distributions were used to calculate ECVs by the iterative statistical
method (10, 11, 18). Each resulting Etest ECV was the MIC that captured 97.5% of the modeled WT
population.
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